Menu
Search
|

Menu

Close
X

Spark Therapeutics Inc ONCE.OQ (NASDAQ Stock Exchange Global Select Market)

50.78 USD
+2.39 (+4.94%)
As of Oct 16
chart
Previous Close 48.39
Open 48.62
Volume 228,260
3m Avg Volume 198,788
Today’s High 51.49
Today’s Low 48.22
52 Week High 96.51
52 Week Low 41.06
Shares Outstanding (mil) 35.82
Market Capitalization (mil) 3,132.52
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.41 Mean rating from 22 analysts

KEY STATS

Revenue (mm, USD)
FY18
41
FY17
12
FY16
20
FY15
22
EPS (USD)
FY18
0.820
FY17
-7.744
FY16
-4.276
FY15
-2.124
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.69
Price to Sales (TTM)
vs sector
153.83
5.82
Price to Book (MRQ)
vs sector
11.96
4.90
Price to Cash Flow (TTM)
vs sector
--
22.98
Total Debt to Equity (MRQ)
vs sector
0.60
16.96
LT Debt to Equity (MRQ)
vs sector
0.47
12.63
Return on Investment (TTM)
vs sector
-61.15
14.32
Return on Equity (TTM)
vs sector
-63.88
16.04

EXECUTIVE LEADERSHIP

Steven Altschuler
Independent Chairman of the Board, Since 2013
Salary: --
Bonus: --
Katherine High
President, Head of Research and Development and Director, Since 2017
Salary: $448,654.00
Bonus: $261,984.00
Jeffrey Marrazzo
Chief Executive Officer, Co-Founder, Director, Since 2016
Salary: $563,462.00
Bonus: $448,328.00
Stephen Webster
Chief Financial Officer, Since 2014
Salary: $414,423.00
Bonus: $219,535.00
John Furey
Chief Operating Officer, Since 2016
Salary: $38,077.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3737 Market St Ste 1300
PHILADELPHIA   PA   19104-5543

Phone:

Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.

SPONSORED STORIES